Plasma kinetics of a chylomicron-like emulsion in patients with coronary artery disease

Atherosclerosis

Volumn 126, Issue 1, 1996, Pages 15-25

  Maranhão, Raul C ^a   Feres, Márcia C ^a   Martins, Márcia T ^a   Mesquita, Carlos H ^b   Toffoletto, Odaly ^a   Vinagre, Carmen G C ^a   Gianinni, Sergio D ^a   Pileggi, Fulvio ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Inst do C do H das C da FMUSP ^*

Author keywords

Cholesterol; Chylomicrons; Coronary artery disease; Emulsions; Lipoproteins; Triglycerides

Indexed keywords

CHYLOMICRON; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG CLEARANCE; FOOD INTAKE; HUMAN; HUMAN EXPERIMENT; HYPERTRIGLYCERIDEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0030603980     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(96)05889-3     Document Type: Article

References (38)

1. [1] Hazzard WR, Bierman EL. Delayed clearance of chylomicron remnants following vitamin A-containing oral fat load in broad-B disease (type III hypercholesterolemia). Metab Clin Exp 1976;25:777.
2. [2] Carlson LA, Rössner S. A methodological study of an intravenous fat tolerance test with Intralipid emulsion. Scand J Clin Lab Invest 1972;29:272.
3. [3] Rössner S, Boberg J, Carlson LA, Freyschuss L, Lassers BW. Comparison between fractional turnover rate of endogenous plasma triglycerides and of Intralipid (intravenous fat tolerance test) in man. Europ J Clin Invest 1974;4:109.
4. [4] Redgrave TG, Maranhão RC. Metabolism of protein-free lipid emulsion models of chylomicrons in rats. Biochim Biophys Acta 1985;835:104.
5. [5] Maranhão RC, Tercyak AM, Redgrave TG. Effects of cholesterol content on the metabolism of protein-free emulsion models of lipoproteins. Biochim Biophys Acta 1986;247.
6. [6] Hultin M, Carneheim C, Rosenqvist K, Olivecrona T. Intravenous lipid emulsions: removal mechanisms as compared to chylomicrons. J Lipid Res 1995;36:2174.
7. [7] Maranhão RC, Roland IA, Hirata MH. Effects of Triton WR 1339 and heparin on the transfer of surface lipids from triglyceride-rich emulsions to high density lipoproteins in rats. Lipids 1990;25:701.
8. [8] Oliveira HCF, Hirata MH, Redgrave TG, Maranhão RC. Competition between chylomicrons and their remnants for plasma removal. Biochim Biophys Acta 1988;958:211.
9. [9] Redgrave TG, Ly HL, Quintão ECR, Ramberg CF, Boston RC. Clearance from plasma of triacylglycerol and cholesteryl ester after intravenous injection of chylomiron-like emulsions in rats and man. Biochem J 1992;293:843.
10. [10] Nakandakare ER, Lottenberg SA, Oliveira HCF, Berlolami MC, Vasconcelos KS, Sperotto G, Quintão ECR. Simultaneous measurements of chylomicron lipolysis and remnant removal using a doubly labeled artificial lipid emulsion: studies in normolipidemic and hyperlipidemic subjects. J Lipid Res 1994;35:143.
11. [11] Frederickson DS, Lees RS. System for phenotyping hyperlipoproteinemia. Circulation 1965;31:321.
12. [12] Beaumont JL, Carlson LA, Cooper GR, Fejfar Z, Frederickson DS, Strasser T. Classification of hyperlipidemias and hyperlipoproteinemias. Bull WHO 1970;43:891.
13. [13] Redgrave TG, Roberts DCK, West, CE. Separation of plasma lipoprotein by density-gradient ultracentrifugation. Anal Biochem 1975;65:42.
14. 131I-labeled plasma proteins. Phys Med Biol 1957;2:36.
15. [15] Radiation Protection. ICRP publication 30. Part I. Limits for Intakes of radionuclides by workers. In: Sowby FS. (ed). Oxford, England: Pergamon, 1984.
16. [16] Smith RM. Dose estimate techniques. In: Rollo FD (ed). Nuclear medicine physics, instrumentation and agents. Saint Louis, USA: C.V. Mosby, 1977;14:513.
17. [17] Margot T, Frein Y, Champarnaud G, Cheruy A, Lutton C. Origin and fate of rat plasma cholesterol in vivo. Modelling of cholesterol movements between plasma and organs. Biochim Biophys Acta 1987;921:587.
18. [18] Boxenbaum H, Ronfeld R. Interspecies pharmacokinetic scaling and the Dedrick plots. Am J Physiol 1983;245:R768.
19. [19] Biology Data Book. In: Altman PL and Dittmer DS. (eds). Federation of the American Societies for Experimental Biology, vol III. Bethesda, Md. 1974;183.
20. [20] Maranhão RC, Quintão ECR. Long term steroid metabolism balance studies in subjects on cholesterol-free and cholesterol-rich diets: comparison between normal and hypercholesterolemic individuals. J Lipid Res 1983;24:167.
21. [21] Perry-Sprawls JR. Physical Principles of Medical Imaging. Aspen Publishers, 1987;485.
22. [22] Snedecor GW, Cochran WG. Statistical Methods. The Iowa State University Press, Ames, 1980;507.
23. [23] Zilversmit DB, Hughes LB, Palmer J. Stimulation of cholesterol ester exchange by lipoprotein-free rabbit plasma. Biochem Biophys Acta 1975;409:393.
24. [24] Berr F, Kern F: Plasma clearance of chylomicrons labeled with retinyl palmitate in healthy human subjects. J Lipid Res 1984;25:805.
25. [25] Brunzell JD, Hazzard WR, Porte Jr D, Bierman EL. Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J Clin Invest 1973;52:1578.
26. [26] Bernardes-Silva H, Toffoletto O, Bortolotto LA, Latrilha MCM, Krieger EM, Pileggi F, Maranhão RC. Malignant hypertension is accompanied by marked alterations in chylomicron metabolism. Hypertension 1995;26:1207.
27. [27] Borensztajn J, Getz GS, Kotlar TJ. Uptake of chylomicron remmants by the liver: further evidence of the modulating role of phospholipids. J Lipid Res 1988;29:1087.
28. [28] Weintraub MS, Eisenberg S, Breslow JL. Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E. J Clin Invest 1987;80:1571.
29. [29] Zilversmit DB. Atherosclerosis: a post-prandial phenomenum. Circulation 1979;60:473.
30. [30] Simpson HS, Williamson CM, Olivecrona T, Pringle S, Maclean J, Lorimer AR, Bonnefous F, Bogaievsky Y, Packard CJ, Shepherd J. Postprandial lipemia, fenofibrate and coronary artery disease. Atherosclerosis 1990;85:193.
31. [31] Groot PHE, van Stiphout WAHJ, Krauss XH, Jansen J, van Tol E, van Ramshorst E, Chin-On S, Hofman A, Cresswell SR: Post-prandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arteriosclerosis Thromb 1991;11:653.
32. [32] Patsch JR, Miesenböck G, Hopferwieser T, Mühlberger V, Knapp E, Dlunn JK, Gotto Jr. AM, Patsch W. Relation of triglyceride metabolism and coronary artery disease. Studies in the post-prandial state. Arteriosclerosis Thromb 1992;12:1336.
33. [33] Simons LA, Dwyer T, Simons J, Bernstein L, Mock P, Poonia NS, Balasubramaniam S, Bron D, Branson J, Morgan J, Roy P. Chylomicrons and chylomicron remnants in coronary artery disease: a case-control study. Atherosclerosis 1987;65:181.
34. [34] Florén CH, Albers JJ, Bierman EL: Uptake of chylomicron remnants causes cholesterol accumulation in cultured human arterial smooth muscle cells. Biochim Biophys Acta 1981;663:336.
35. [35] Araujo FB, Barbosa DS, Hsin CY, Maranhão RC, Abdalla DSP. Evaluation of oxidative stress in patients with hyperlipidemia. Atherosclerosis 1995;11:61.
36. [36] Bellinati-Pires R, Waitzberg DL, Salgado MM, Carneiro-Sampaio MMS. Functional alterations of human neutrophils by medium chain tryglyceride emulsions: evaluation of phagocythosis, bacterial killing, and oxidative activity. J Leukocyte Biol 1993;53:404.
37. [37] Görög P. Activation of human blood monocytes by oxidized polyunsaturated fatty acids: a possible mechanism for the generation of lipid peroxides in the circulation. Int J Exp Path 1991;72:227.
38. [38] Slyper ADH. A fresh look at the atherogenic remnant hypothesis. Lancet 1992;340:289.